Liposomes equipped with cell penetrating peptide BR2 enhances chemotherapeutic effects of cantharidin against hepatocellular carcinoma

References

• Deshayes S, Morris MC, Divita G et al. (2005). Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 62:1839–49.
   PubMed Web of Science ®Google Scholar
• Deshpande PP, Biswas S, Torchilin VP. (2013). Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond) 8:1509–28.
   PubMed Web of Science ®Google Scholar
• He C, Hu Y, Yin L et al. (2010). Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31:3657–66.
   PubMed Web of Science ®Google Scholar
• Jang JH, Kim YJ, Kim H et al. (2015). Buforin IIb induces endoplasmic reticulum stress-mediated apoptosis in HeLa cells. Peptides 69:144–9.
   PubMed Web of Science ®Google Scholar
• Janssens V, Goris J. (2001). Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353:417–39.
   PubMed Web of Science ®Google Scholar
• Kang T, Jiang M, Jiang D et al. (2015). Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin/transferrin receptor complex. Mol Pharm Pharm 12:2947–61.
   PubMed Web of Science ®Google Scholar
• Koren E, Torchilin VP. (2012). Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 18:385–93.
   PubMed Web of Science ®Google Scholar
• Lee HS, Park CB, Kim JM et al. (2008). Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett 271:47–55.
   PubMed Web of Science ®Google Scholar
• Leuschner C, Hansel W. (2004). Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des 10:2299–310.
   PubMed Web of Science ®Google Scholar
• Li YM, Mackintosh C, Casida JE. (1993). Protein phosphatase 2A and its [3H]cantharidin/[3H]endothall thioanhydride binding site. Inhibitor specificity of cantharidin and ATP analogues. Biochem Pharmacol 46:1435–43.
   PubMed Web of Science ®Google Scholar
• Liang DS, Su HT, Liu YJ et al. (2015). Tumor-specific penetrating peptides-functionalized hyaluronic acid-d-alpha-tocopheryl succinate based nanoparticles for multi-task delivery to invasive cancers. Biomaterials 71:11–23.
   PubMed Web of Science ®Google Scholar
• Lim KJ, Sung BH, Shin JR et al. (2013). A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. PLoS One 8:e66084.
   PubMed Web of Science ®Google Scholar
• Liu D, Chen Z. (2009). The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem 9:392–6.
   PubMed Web of Science ®Google Scholar
• Maitani Y, Hattori Y. (2009). Oligoarginine-PEG-lipid particles for gene delivery. Expert Opin Drug Deliv 6:1065–77.
   PubMed Web of Science ®Google Scholar
• Marquina G, Waki H, Fernandez LE et al. (1996). Gangliosides expressed in human breast cancer. Cancer Res 56:5165–71.
   PubMed Web of Science ®Google Scholar
• Mehdinia A, Asiabi M, Jabbari A et al. (2011). Analysis of cantharidin in false blister beetles (Coleoptera: Oedemeridae) by headspace solid-phase microextraction and gas chromatography-mass spectrometry. J Chromatogr B 879:2897–901.
   PubMed Web of Science ®Google Scholar
• Mehta G, Hsiao AY, Ingram M et al. (2012). Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release 164:192–204.
   PubMed Web of Science ®Google Scholar
• Mikhail AS, Eetezadi S, Ekdawi SN et al. (2014). Image-based analysis of the size- and time-dependent penetration of polymeric micelles in multicellular tumor spheroids and tumor xenografts. Int J Pharm 464:168–77.
   PubMed Web of Science ®Google Scholar
• Oaks WW, Ditunno JF, Magnani T et al. (1960). Cantharidin poisoning. Arch Intern Med 105:574–82.
   PubMedGoogle Scholar
• Pang RW, Lee TK, Man K et al. (2006). PIN1 expression contributes to hepatic carcinogenesis. J Pathol 210:19–25.
   PubMed Web of Science ®Google Scholar
• Papo N, Shai Y. (2003). New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 42:9346–54.
   PubMed Web of Science ®Google Scholar
• Pattni BS, Chupin VV, Torchilin VP. (2015). New developments in liposomal drug delivery. Chem Rev 115:10938–66.
   PubMed Web of Science ®Google Scholar
• Rauh R, Kahl S, Boechzelt H et al. (2007). Molecular biology of cantharidin in cancer cells. Chin Med 2:8.
   PubMedGoogle Scholar
• Schindelin J, Arganda-Carreras I, Frise E et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat Meth 9:676–82.
   PubMed Web of Science ®Google Scholar
• Tanno M, Yamada H, Kyomasu Y et al. (1993). Immunohistochemical localization of ganglioside components in hepatocellular carcinoma and liver cirrhosis using monoclonal antibody. Lab Invest 68:456–64.
   PubMed Web of Science ®Google Scholar
• Tenschert W, Behrenbeck T, Rolf N et al. (1987). Cantharidin poisoning. Transitory impairment of kidney function and hemorrhagic cystitis. Fortschr Med 105:686–8.
   PubMedGoogle Scholar
• Torchilin VP, Levchenko TS. (2003). TAT-liposomes: a novel intracellular drug carrier. Curr Protein Pept Sci 4:133–40.
   PubMed Web of Science ®Google Scholar
• van der Veldt AA, Hendrikse NH, Smit EF et al. (2010). Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imag 37:1950–8.
   PubMed Web of Science ®Google Scholar
• Walrant A, Matheron L, Cribier S et al. (2013). Direct translocation of cell-penetrating peptides in liposomes: A combined mass spectrometry quantification and fluorescence detection study. Anal Biochem 438:1–10.
   PubMed Web of Science ®Google Scholar
• Wong BC, Zhang H, Qin L et al. (2014). Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro. Drug Des Dev Ther 8:993–1001.
   PubMed Web of Science ®Google Scholar
• Xiang B, Dong DW, Shi NQ et al. (2013). PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. Biomaterials 34:6976–91.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang Y, Xie X et al. (2014). PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy. Biomaterials 35:4368–81.
   PubMed Web of Science ®Google Scholar
• Ye JN, Gu TG, Xia LA et al. (1990). Enhanced expression of ganglioside GD3 in human and rat hepatocellular carcinoma cells and NIH 3T3 cells transfected with human tumor DNAs. Cancer Res 50:7697–702.
   PubMed Web of Science ®Google Scholar
• Zhang DD, Wang JX, Xu DG. (2016a). Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems. J Control Release 229:130–9.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lu L, Zhang L et al. (2016b). Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide. Sci Rep 6:19800.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Tang J, Fu L et al. (2013). A pH-responsive alpha-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials 34:7980–93.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ng HL, Lu A et al. (2016c). Drug delivery system targeting advanced hepatocellular carcinoma: current and future. Nanomedicine NBM 12:853–69.
   PubMed Web of Science ®Google Scholar
• Zhu D, Tao W, Zhang H et al. (2016). Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Acta Biomater 30:144–54.
   PubMed Web of Science ®Google Scholar